Herbs & Supplements

References

Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: from bench to bed side. Anticancer Research. 2006;26(6B):4457-4498.

Agency for Health Care Policy and Research. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Summary. Evidence Report/Technology Assessment Number 21. September 2000. Available at: http://ahcpr.gov/clinic/epscums/milktsum.htm Accessed February 12, 2003.

Anon: Milk thistle. In: DerMarderosian A, Beutler JA, eds. Facts and Comparisons: The Review of Natural Products. St. Louis, MO, Facts and Comparisons. January 1997.

Arizona Board of Regents. An Illustrated Guide to Arizona Weeds. Tucson, Arizona. The University of Arizona Press. 1972. Available at: http://wwwuapress.arizona.edu/online.bks/weds/milkthis.htm Accessed March 6, 2003.

Awang D. Milk thistle. Canadian Pharmaceutical Journal. 1993;126:402-404 and 422.

Bean C. The Nature Conservancy. Element Stewardship Abstract for Silybum marianum. Available at: http://tncweeds.ucdavis.edu/esadocs/documnts/silymar.html Accessed March 6, 2003.

Ball KR, Kowdley KV. A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease. Journal of Clinical Gastroenterology. 2005;39(6):520-528.

Bean P. The use of alternative medicine in the treatment of hepatitis C. American Clinical Laboratory. 2002;21(4):19-21.

Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study of the liver protective effect of silybin-phosphatidylcholine complex (idb1016) in chronic active hepatitis. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 1993. 31(9):456-460.

Chlopcikova S, Psotova J, Miketova P, Simanek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytotherapy Research. 2004;18(2):107-110.

Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Molecular Carcinogens. 2004;40(3):143-149.

Comelli MC, Mengs U, Schneider C, Prosdocimi M. Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integrative Cancer Therapies. 2007;6(2):120-129.

Crocenzi FA, Roma MG. Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Current Medicinal Chemistry. 2006;13(9):1055-1074.

Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, et al. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. Hepatology. 2001;34(2):329-339.

Das SK, Vasudevan DM. Protective effects of silymarin, a milk thistle (Silybium [sic] marianum) derivative on ethanol-induced oxidative stress in liver. Indian Journal of Biochemistry and Biophysics. 2006;43(5):306-311.

Dattner AM. From medical herbalism to phytotherapy in dermatology: back to the future. Dermatological Therapy. 2003;16(2):106-113.

Davis-Searles PR, Nakanishi Y, Kim NC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Research. 2005;65(10):4448-4457.

Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. International Journal of Cancer. 2003;106(5):699-705.

Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis. 2004;25(8):1459-1465.

DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy. 2003;23(7):866-870.

Dryden GW, Song M, McClain C. Polyphenols and gastrointestinal diseases. Current Opinion in Gastroenterology. 2006;22(2):165-170.

Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology. 1989;9(1):105-113.

Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. American Journal of Gastroenterology. 1998;93(2):139-143.

Fraschini F, Demartini G, Esposti D. Pharmacology of silymarin. Clinical Drug Investigation. 2002;22(1):51-65.

Gazak R, Walterova D, Kren V. Silybin and silymarin--new and emerging applications in medicine. Current Medicinal Chemistry. 2007;14(3):315-338.

Giese LA. Milk thistle and the treatment of hepatitis. Gastroenterology Nursing. 2001;24(2):95-97.

Gordon A, Hobbs DA, Bowden DS, et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology. 2006;21(1 Pt 2):275-280.

Greenlee H, Abascal K, Yarnell E, Ladas E. Clinical applications of Silybum marianum in oncology. Integrative Cancer Therapies. 2007;6(2):158-165.

Gurley BJ, Barone GW, Williams DK, et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metabolism and Disposition. 2006;34(1):69-74.

Hernandez R, Nazar E. Effect of silymarin in intrahepatic cholestasis of pregnancy (preliminary communication) [Article in Spanish] Rev Chil Obstet Ginecol. 1982;47(1):22-29.

Hoh C, Boocock D, Marczylo T, et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clinical Cancer Research. 2006;12(9):2944-2950.

Huseini HF, Larijani B, Heshmat R, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytotherapy Research.2006;20(12):1036-1039.

Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. Journal of Medical Food. 2007;10(3):543-547.

Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica. 2002;32(6):451-478.

Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. American Journal of Medicine. 2002;113(6):506-515.

Jellin JM, Gregory P, Batz F, Hitchens K, et al, eds. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Comprehensive Database, 3rd Edition. Stockton CA: Therapeutic Research Facility, 2000.

Johnson VJ, He Q, Osuchowski MF, Sharma RP. Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Medica. 2003;69(1):44-49.

Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evidence Based Complementary and Alternative Medicine. 2005;2(3):383-386.

Katiyar SK. UV-induced immune suppression and photocarcinogenesis: Chemoprevention by dietary botanical agents. Cancer Letter. 2007;255(1):1-11.

Kiruthiga PV, Shafreen RB, Pandian SK, Arun S, Govindu S, Devi KP. Protective effect of silymarin on erythrocyte haemolysate [sic] against benzo(a)pyrene and exogenous reactive oxygen species (H2O2) induced oxidative stress. Chemosphere. 2007;68(8):1511-1518.

Kohno H, Tanaka T, Kawabata K, et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. International Journal of Cancer. 2002;101(5):461-468.

Krecman V, Skottova N, Walterova D, Ulrichova J, Simanek V. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Medica. 1998;64(2):138-142.

Ladas EJ, Kelly KM. Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? Journal of Alternative and Complementary Medicine. 2003;9(3):411-416.

Lee DG, Kim HK, Park Y, et al. Gram-positive bacteria specific properties of silybin derived from Silybum marianum. Archives of Pharmaceutical Research. 2003;26(8):597-600.

Lee LS, Andrade AS, Flexner C. Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clinical Infectious Diseases. 2006;43(8):1052-1059.

Li LH, Wu LJ, Tashiro S, Onodera S, Uchiumi F, Ikejima T. Silibinin prevents UV-induced HaCaT cell apoptosis partly through inhibition of caspase-8 pathway. Biology and Pharmacy Bulletin. 2006;29(6):1096-1101.

Li LH, Wu LJ, Tashiro S, Onodera S, Uchiumi F, Ikejima T. Silibinin prevents UV-induced HaCaT cell apoptosis partly through inhibition of Caspase-8 pathway. Biology and Pharmacy Bulletin. 2006;29(6):1096-1101.

Li LH, Wu LJ, Zhou B, et al. Silymarin prevents UV irradiation-induced A375-S2 cell apoptosis. Biology and Pharmacology Bulletin. 2004;27(7):1031-1036.

Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. Journal of Clinical Gastroenterology. 2003;37(4):336-339.

Maghrani M, Zeggwagh NA, Lemhadri A, El Amraoui M, Michel JB, Eddouks M. Study of the hypoglycaemic [sic] activity of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes mellitus. Journal of Ethnopharmacology. 2004;91(2-3):309-316.

Malewicz B, Wang Z, Jiang C, et al. Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements. Carcinogenesis. 2006;27(9):1739-1747.

Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. Journal of Viral Hepatitis. 2005;12(6):559-567.

McCarty MF. Potential utility of natural polyphenols for reversing fat-induced insulin resistance. Medical Hypotheses. 2005;64(3):628-635.

Mills E, Wilson K, Clarke M, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. European Journal of Clinical Pharmacology. 2005;61(1):1-7.

Muriel P, Mourelle M. The role of membrane composition in ATPase activities of cirrhotic rat liver: effect of silymarin. Journal of Applied Toxicology. 1990;10(4):281-284.

National Cancer Institute. Milk thistle (PDQ). Health professional version. Last modified June 23, 2004. Available at: www.nci.nih.gov/cancertopics/ pdq/cam/milkthistle/healthprofessional/allpages. Accessed October 14, 2004.

Natural Medicines Comprehensive Database, Online Edition. Pharmacist's Letter/Prescriber's Letter. Stockton CA: Therapeutic Research Facility, 2006. Available at: http://www.pharmacistsletter.com/(S(ulqz3s45omt3ag55um4kj345))/home.aspx?li=1&st=1&cs=&s=ND.

Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. Journal of Hepatology. 1998. 28(4):615-621.

Peirce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: Stonesong Press; 1999.

Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy. 2002;22(5):551-556.

Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integrative Cancer Therapies. 2007;6(2):104-109.

Qi L, Singh RP, Lu Y, Agarwal R, et al. Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biology and Therapeutics. 2003;2(5):526-531.

Rainone F. Milk thistle. American Family Physician. 2005;72(7):1285-1258.

Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Systematic Review. 2005;(2):CD003620.

Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. American Journal of Gastroenterology. 2005;100(11):2583-2591.

Sagar SM. Future directions for research on Silybum marianum for cancer patients. Integrative Cancer Therapies. 2007;6(2):166-173.

Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-2063.

Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin. Forsch Komplementarmed. 2007;14(2):70-80.

Scambia G, De Vincenzo R, Ranelletti FO, et al. Antiproliferative effect of silybin on gynaecological [sic] malignancies: synergism with cisplatin and doxorubicin. European Journal of Cancer. 1996;32A(5):877-882.

Seidlova-Wuttke D, Becker T, Christoffel V, Jarry H, Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. Journal of Steroid Biochemistry and Molecular Biology. 2003;86(2):179-188.

Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. European Journal of Cancer. 2005;41(13):1969-1979.

Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Current Cancer Drug Targets. 2004;4(1):1-11.

Singh RP, Deep G, Chittezhath M, et al. Effect of silibinin on the growth and progression of primary lung tumors in mice. Journal of the National Cancer Institute. 2006;98(12):846-855.

Skottova N, Krecman V. Silymarin as a potential hypocholesterolaemic [sic] drug. Physiology Research. 1998;47(1):1-7.

Skottova N, Vecera R, Urbanek K, Vana P, Walterova D, Cvak L. Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacology Research. 2003;47(1):17-26.

Somogyi A, Ecsedi GG, Blazovics A, Miskolczi K, Gergely P, Feher J. Short term treatment of type II hyperlipoproteinaemia [sic] with silymarin. Acta Medica Hungaria. 1989;46(4):289-295.

Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metabolism and Disposition. 2004;32(6):587-594.

Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Digestive and Liver Diseases. 2007;39(4):293-304.

Svagera Z, Skottova N, Vana P, et al. Plasma lipoproteins in transport of silibinin, an antioxidant flavonolignan from Silybum marianum. Phytotherapy Research. 2003;17(5):524-530.

Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integrative Cancer Therapies. 2007;6(2):146-157.

Thelen P, Jarry H, Ringert RH, Wuttke W. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells. Planta Medica. 2004;70(5):397-400.

Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. Journal of Urology. 2004;171(5):1934-1938.

Toklu HZ, Tunali-Akbay T, Erkanli G, Yuksel M, Ercan F, Sener G. Silymarin, the antioxidant component of Silybum marianum, protects against burn-induced oxidative skin injury. Burns. 2007;33(7):908-916.

Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncology Reports. 2004;11(2):493-499.

Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 2004;25(9):1711-1720.

Tyagi AK, Agarwal C, Singh RP, Shroyer KR, Glode LM, Agarwal R. Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochemistry and Biophysics Research Communications. 2003;312(4):1178-1184.

Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate. 2002;53(3):211-217.

van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metabolism Review. 2006;38(3):477-514.

van Erp NP, Baker SD, Zhao M, et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clinical Cancer Research. 2005;11(21):7800-7806.

Vaknin Y, Hadas R, Schafferman D, Murkhovsky L, Bashan N. The potential of milk thistle (Silybum marianum L.), an Israeli native, as a source of edible sprouts rich in antioxidants. International Journal of Food Science and Nutrition. Epublished ahead of print. August 20, 2007.

Varga Z, Ujhelyi L, Kiss A, Balla J, Czompa A, Antus S. Effect of silybin on phorbol myristate actetate-induced protein kinase C translocation, NADPH oxidase activity and apoptosis in human neutrophils. Phytomedicine. 2004;11(2-3):206-212.

Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clinical Cancer Research. 2005;11(23):8441-8448.

Wilasrusmee C, Kittur S, Shah G, et al. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Medical and Science Monitor. 2002;8(11):BR439-BR443.

Wu DF, Peng RX, Ye LP, Yu P. The effects of silymarin on hepatic microsomal and mitochondrial membrane fluidity in mice. [Article in Chinese] Zhongguo Zhong Yao Za Zhi. 2003 Sep;28(9):870-872.

Yoo HG, Jung SN, Hwang YS, et al. Involvement of NF-kappaB and caspases in silibinin-induced apoptosis of endothelial cells. International Journal of Molecular Medicine. 2004;13(1):81-86.

Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis. 1999;20(11):2101-2108.

Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metabolism Review. 2004;36(1):57-104.

Zhou B, Wu LJ, Tashiro S, Onodera S, Uchiumi F, Ikejima T. Silibinin protects rat cardiac myocyte from isoproterenol-induced DNA damage independent on regulation of cell cycle. Biology and Pharmacy Bulletin. 2006;29(9):1900-1905.

Zielinska-Przyjemska M, Wiktorowicz K. An in vitro study of the protective effect of the flavonoid silydianin against reactive oxygen species. Phytotherapy Research. 2006;20(2):115-119.

Last Revised October 16, 2007